Clinical Evidence

Explore the clinical evidence shaping the probiotics market today

Filter by Wellness Area

Therapeutical Areas to Clinical Evidence (desktop)
  • All
  • Weight Management
  • Gastrointestinal health
  • Pediatric health
  • Oral health
  • Cardiometabolic health
  • Immune health
  • Cognitive health
  • Skin health
  • Women's health
  • Eye health
Therapeutical Areas to Clinical Evidence (mobile)

Filter by Product

Products to Clinical Evidence (desktop)
  • All
  • KABP® Intensive G.I
  • KABP® Urinary Tract Support
  • KABP® Mature Immune Defense®
  • KABP® DENTALAC
  • LipiGO®
  • KABP® Digest
  • Brain (DR7)®
  • DR7
  • KABP® DENTISANI
  • KABP® Baby Colic
  • KABP® Vaginal Health Balance
  • KABP Cardio
  • KABP®-051
  • AB-Protears®
  • Kaneka Probiotics L.sakei proBio65 ®
  • KABP 21®
  • KABP® MENOPAUSE
Products to Clinical Evidence (mobile)
  • Clinical and Metabolomic Effects of Lactiplantibacillus plantarum and Pediococcus acidilactici in Fructose Intolerant Patients

    2022

    Portincasa, et al

    Read
  • A probiotic blend improves defecation, mental health, and productivity in healthy Japanese volunteers under stressful situations

    2022

    Sato, et al

    Read
  • Combination of a probiotic and an antispasmodic increases quality of life and reduces symptoms in patients with irritable bowel syndrome: a pilot study

    2020

    Barraza-Ortiz DA, et al

    Read
  • Efficacy of probiotic i3.1 symptomatic improvement in patients with lactose intolerance

    2020

    Cano-Contreras A, et al

    Read
  • Derived postbiotics of a multi‐strain probiotic formula clinically validated for the treatment of Irritable Bowel Syndrome

    2020

    Perez M, et al

    Read
  • Comparative effect of the i3.1 probiotic formula in two animal models of colitis

    2017

    Lorén V, et al

    Read
  • i.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life

    2014

    Lorenzo-Zúñiga V, et al

    Read